Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Objective: The global rise in gabapentinoid prescriptions for chronic pain has been striking. However, this trend has been accompanied by growing concerns about misuse and dependence. This qualitative systematic review aimed to synthesise the perspectives of healthcare practitioners and other professionals on these emerging challenges.

Databases And Data Treatment: Six databases (MEDLINE, Scopus, Web of Science, CINAHL, EMBASE, PsycINFO) were searched to May 2025. Eligible studies used qualitative or mixed methods to explore professional views on gabapentinoid misuse or dependence. Studies focusing solely on patient perspectives or therapeutic use were excluded. Methodological quality was assessed using the Critical Appraisal Skills Programme checklist. Data were analysed using thematic synthesis, and confidence in the findings was evaluated using GRADE-CERQual.

Results: After screening 1584 records, 19 original studies were included. Most were conducted in substance use treatment and law enforcement settings, where professionals frequently encounter vulnerable populations and more severe patterns of misuse than in general clinical care. Reported drivers of misuse included polydrug use, opioid substitution, psychological distress and poor access to non-pharmacological care. Signs of misuse included early refills, dose escalation and reluctance to taper. Professionals described ethical tensions in prescribing and dispensing and proposed harm reduction strategies, including prescriber education, regulatory reform, expanded treatment access and public awareness.

Conclusions: Gabapentinoid misuse is shaped by clinical, social and structural factors. Tackling these challenges requires systemic responses that go beyond individual prescribers. Lessons from opioid policy responses should inform balanced, compassionate and evidence-informed strategies to reduce harm and improve care.

Significance Statement: This is the first systematic review to synthesise professional perspectives on gabapentinoid misuse and dependence, drawing on studies from Europe, North America, the Middle East and Africa. Integrating insights from healthcare, law enforcement and policy settings, it reveals the structural drivers behind rising misuse-including opioid regulation, socioeconomic hardship and limited access to alternatives-and highlights gaps in clinical guidance. The findings offer actionable, cross-sector strategies to support safer prescribing, informed policy and more effective harm reduction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402873PMC
http://dx.doi.org/10.1002/ejp.70116DOI Listing

Publication Analysis

Top Keywords

gabapentinoid misuse
16
misuse dependence
16
systematic review
12
perspectives gabapentinoid
8
misuse
8
law enforcement
8
misuse included
8
harm reduction
8
gabapentinoid
5
studies
5

Similar Publications

Background And Objective: The global rise in gabapentinoid prescriptions for chronic pain has been striking. However, this trend has been accompanied by growing concerns about misuse and dependence. This qualitative systematic review aimed to synthesise the perspectives of healthcare practitioners and other professionals on these emerging challenges.

View Article and Find Full Text PDF

Background: Following recent developments regarding gabapentinoid (i.e., pregabalin and gabapentin) abuse and misuse in France, this study aims to describe new users of gabapentinoids from 2017 to 2021, estimate the incidence of high-dose use, and identify the associated factors.

View Article and Find Full Text PDF

Gabapentinoids, including Gabapentin and Pregabalin, are increasingly misused, particularly by individuals with psychiatric comorbidities or prior substance use. This case series highlights three patients, including one adolescent, who developed dependence on ultra-high doses of Gabapentinoids. Presenting patterns included use for euphoria, self-medication, and anxiety relief.

View Article and Find Full Text PDF

Pregabalin and gabapentin use in France from 2012 to 2023, impact of prescription restrictions, a time series analysis.

Int J Drug Policy

July 2025

General Practice Department, University of Versailles - Saint Quentin en Yvelines, 2 avenue de la source de la Bièvre, 78180, Montigny le Bretonneux, France; Center for Research in Epidemiology and Population Health, The French National Institute of Health and Medical Research, INSERM U1018 Equipe

Introduction: Gabapentinoids use is accompanied by increased misuse, particularly for pregabalin. In May 2021, France introduced secure prescription requirements for pregabalin. This paper aims to analyse variations in gabapentinoid dispensing, with a focus on changes in prescription rules.

View Article and Find Full Text PDF

Background: Gabapentinoid, including Gabapentin and Pregabalin, are commonly used for approved and off-label health conditions, but their misuse with opioid among individuals with substance use disorder (SUD) increases the risk of respiratory depression and death. Thus, we investigated the impact of SUD on different health outcomes among the Gabapentinoid users in the U.S.

View Article and Find Full Text PDF